Loading
A phase 3 trial testing JSKN016 in triple-negative breast cancer, now recruiting.
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care is a phase 3 interventional study registered as NCT07533123, led by Jiangsu Alphamab Biopharmaceuticals, and recruiting on the registry. Official title: A Randomised, Controlled, Open-Label Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Triple-Negative Breast Cancer Who Have Failed at Least Two Lines of Prior Systemic Therapy. Planned enrolment is 364 participants (estimated). The study started in 2026-03-17 and primary completion is expected in 2029-03-17. No results have been posted on ClinicalTrials.gov.
Shares JSKN016, Alphamab Oncology.
Shares JSKN016, Alphamab Oncology.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).